2020
Sublingual Oxytocin With Clozapine in a Patient With Persisting Psychotic Symptoms, Suicidal Thinking With Self-Harm.
Garakani A, Buono FD, Marotta RF. Sublingual Oxytocin With Clozapine in a Patient With Persisting Psychotic Symptoms, Suicidal Thinking With Self-Harm. Journal Of Clinical Psychopharmacology 2020, 40: 507-509. PMID: 32701906, DOI: 10.1097/jcp.0000000000001248.Peer-Reviewed Case Reports and Technical Notes
2016
Neuropsychiatric aspects of concussion
Radhakrishnan R, Garakani A, Gross LS, Goin MK, Pine J, Slaby AE, Sumner CR, Baron DA. Neuropsychiatric aspects of concussion. The Lancet Psychiatry 2016, 3: 1166-1175. PMID: 27889010, DOI: 10.1016/s2215-0366(16)30266-8.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsBrain ConcussionBrain Injuries, TraumaticDiagnosis, DifferentialHumansRandomized Controlled Trials as TopicTreatment OutcomeConceptsTraumatic brain injuryBrain injuryDirect head traumaProspective clinical trialsEffective treatment interventionsNon-contact sportsHistory of lossHead traumaNeuropsychiatric symptomsPatient populationPsychiatric morbidityClinical trialsNeuropsychiatric aspectsTreatment responseElderly individualsContact sportsReliable biomarkersPsychiatric cliniciansTreatment interventionsClinical phenotypeConcussionMild formRelevant outcomesInjuryPatients
2013
Electroconvulsive Therapy (ECT) for Catatonia in a Patient With Schizophrenia and Synthetic Cannabinoid Abuse
Leibu E, Garakani A, McGonigle DP, Liebman LS, Loh D, Bryson EO, Kellner CH. Electroconvulsive Therapy (ECT) for Catatonia in a Patient With Schizophrenia and Synthetic Cannabinoid Abuse. Journal Of Ect 2013, 29: e61-e62. PMID: 23670023, DOI: 10.1097/yct.0b013e318290fa36.Peer-Reviewed Case Reports and Technical NotesMeSH KeywordsAdultCannabisCatatoniaDesigner DrugsElectroconvulsive TherapyHumansMaleMarijuana AbuseSchizophreniaTreatment OutcomeTransient Febrile Reaction After Electroconvulsive Therapy (ECT) in a Young Adult With Intellectual Disability and Bipolar Disorder
Majeske MF, Garakani A, Maloutas E, Bryson EO, Kellner CH. Transient Febrile Reaction After Electroconvulsive Therapy (ECT) in a Young Adult With Intellectual Disability and Bipolar Disorder. Journal Of Ect 2013, 29: e63-e65. PMID: 23774055, DOI: 10.1097/yct.0b013e3182972b8c.Peer-Reviewed Case Reports and Technical NotesMeSH KeywordsAdultBipolar DisorderElectroconvulsive TherapyFemaleFeverHumansIntellectual DisabilityTreatment OutcomeConceptsElectroconvulsive therapyECT treatmentManic symptomsIntellectual disabilityBipolar disorderUse of ECTAdditional ECT treatmentsMultiple medication trialsTransient febrile reactionMild-moderate intellectual disabilityFever workupTransient feverMedication trialsFebrile reactionsPressured speechManic statePatient's motherPsychiatric disordersPatientsYoung adultsDisordersFeverTreatmentTherapySymptoms
2012
Cerebrospinal fluid levels of glutamate and corticotropin releasing hormone in major depression before and after treatment
Garakani A, Martinez JM, Yehuda R, Gorman JM. Cerebrospinal fluid levels of glutamate and corticotropin releasing hormone in major depression before and after treatment. Journal Of Affective Disorders 2012, 146: 262-265. PMID: 22840611, DOI: 10.1016/j.jad.2012.06.037.Peer-Reviewed Original Research
2008
A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder
Garakani A, Martinez JM, Marcus S, Weaver J, Rickels K, Fava M, Hirschowitz J. A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder. International Clinical Psychopharmacology 2008, 23: 269-275. PMID: 18703936, DOI: 10.1097/yic.0b013e328301a74c.Peer-Reviewed Original ResearchConceptsMontgomery-Asberg Depression Rating Scale scoreMajor depressive disorderDepression Rating Scale scoresHamilton Anxiety ScaleRating Scale scoresPlacebo groupDepressive disorderScale scoreCGI improvement scoreCombination of quetiapinePlacebo-controlled trialClinical global improvementWeeks of treatmentOnset of actionMixed effects linear regressionQuetiapine augmentationAnxiety ScaleFluoxetine groupFluoxetine treatmentCGI scoresImproved sleepMixed effects regressionInsomnia scoresQuetiapineFluoxetineShort-term tolerability of a nonazapirone selective serotonin 1A agonist in adults with generalized anxiety disorder: A 28-day, open-label study
Mathew SJ, Garakani A, Reinhard JF, Oshana S, Donahue S. Short-term tolerability of a nonazapirone selective serotonin 1A agonist in adults with generalized anxiety disorder: A 28-day, open-label study. Clinical Therapeutics 2008, 30: 1658-1666. PMID: 18840371, DOI: 10.1016/j.clinthera.2008.09.006.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAnti-Anxiety AgentsAnxiety DisordersDiagnostic and Statistical Manual of Mental DisordersDrug Administration ScheduleFemaleHumansMaleMiddle AgedPiperazinesPsychiatric Status Rating ScalesSerotonin 5-HT1 Receptor AgonistsSerotonin Receptor AgonistsSingle-Blind MethodSulfonamidesSurveys and QuestionnairesTreatment OutcomeConceptsGeneralized anxiety disorderShort-term tolerabilityAdverse eventsPRX-00023Hamilton Anxiety Rating Scale scoresVital signsResponse criteriaAnxiety disordersTotal scoreOpen-label studySerotonin 1A agonistSingle-blind placeboAnxiety Rating Scale scoresSerious adverse eventsStudy end pointInfluenza-like symptomsOpen-label treatmentPrimary outcome measureDiagnosis of GADRating Scale scoresEnd point changeSample of patientsSerotonin 1A receptorPremature ventricular contractionsSelective partial agonist